Turn on more accessible mode
Skip to main content
Turn off more accessible mode
VISP: Center for Viral Infection Structural Proteomics
Sign In
|
VISP: Center for Viral Infection Structural Proteomics
This Site: VISP: Center for Viral Infection Structural Proteomics
All Sites
People
Advanced Search
VISP: Center for Viral Infection Structural Proteomics
SARS-CoV
Influenza virus
Herpesvirus
Flaviviruses
Poxviruses
VISP: Center for Viral Infection Structural Proteomics
>
VISPCollaboratorPublications
>
Development of novel antivirals against flaviviruses
VISPCollaboratorPublications
: Development of novel antivirals against flaviviruses
Title
Development of novel antivirals against flaviviruses
Authors
Patkar CG, et al.
Abstract
Dengue virus is responsible for a significant amount of human disease in predominantly tropical areas of the world. Much effort has focused on the development of vaccines against the four serotypes of dengue, and within the next few years a vaccine is anticipated. Less progress has been made at developing antivirals that might reduce disease severity. Recent advances in the structural biology of dengue virus and other flaviviruses have opened new possibilities for the rational design of small molecule inhibitors of virus replication. This chapter describes the structural attributes of the dengue virion and how knowledge of its structure, assembly, and entry mechanisms are guiding new strategies toward the development of compounds that will interfere with the viral replication process.
Journal
Novartis Found. Symp.
Date
8/10/2006
Link
PMID: 17319153
Reference
Patkar CG, Kuhn RJ.
Development of novel antivirals against flaviviruses.
Novartis Found Symp.
(2006);277:41-52; discussion 52-6, 71-3, 251-3.
PMID
17319153
Keyword
VISP, FLAVI
Attachments
Created at 3/1/2007 5:32 PM by Sophie Coon
Last modified at 3/1/2007 5:32 PM by Sophie Coon
Use this page to add attachments to an item.
Name